Precocious Puberty News and Research

RSS

LA surgeon develops minimally invasive approach to remove pineal tumors

One of the most difficult-to-remove tumors located deep in the midbrain area can now be safely excised thanks to the work of one Los Angeles surgeon. Hrayr Shahinian, M.D., medical director of The Skull Base Institute in Los Angeles, has developed a minimally invasive approach to removing pineal tumors so called as they are shaped like pine cones.

21 Sep 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases.

23 Dec 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009